-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE: Results from a previous small study showed a favorable safety profile for
OBJECTIVE: Results from a previous small study showed a favorable safety profile for
Methods: The study cohort included pregnant women who were prospectively enrolled in the MotherToBaby/Termatology Informatics study of autoimmune disorders in pregnancy who were receiving HCQ .
Results: Between 2004 and 2018 , 837 pregnant women met the study inclusion criteria, including 279 women who received HCQ during pregnancy and 279 control women who did not receive HCQ .
In this study, there was no evidence of an increased risk of structural birth defects or other adverse outcomes in women treated with HCQ during pregnancy, with the exception of head circumference at birth .
Source: Chambers, CD, Johnson, DL, Xu, R.
Chambers, CD, Johnson, DL, Xu, R.
, Luo, Y.
, Felix, R.
, Fine, M.
, Lessard, C.
, Adam, MP, Braddock, SR, Robinson, LK, Burke, L.
, Jones, KL and (2022), Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study.
Arthritis Rheumatol, 74: 711-724.
https://doi.
org/10.
1002/art.
42015
Leave a comment here